|
|
| Maillet, A; Congy Jolivet, N; Le Guellec, S; Vecellio, L; Hamard, S; Courty, Y; Courtois, Anthony; Gauthier, F; Diot, P; Thibault, G; Lemarie, E; Heuze Vourc' H, N. |
| Purpose. Despite an increasing interest in the use of inhalation for local delivery of molecules for respiratory diseases and systemic disorders, methods to deliver therapy through air-ways has received little attention for lung cancer treatment. However, inhalation of anticancer drugs is an attractive alternative route to systemic administration which results in limited concentration of the medication in the lungs, and triggers whole-body toxicity. In this study, we investigated the feasibility of nebulization for therapeutic antibodies, a new class of fully-approved anticancer drugs in oncology medicine. Materials and methods. Cetuximab, a chimeric IgG1 targeting the epidermal growth factor receptor (EGER), was nebulized using three types of delivery... |
| Tipo: Text |
Palavras-chave: Nebulizer; Lung cancer; Cetuximab; Anticancer antibody; Aggregation; Aerosol. |
| Ano: 2008 |
URL: http://archimer.ifremer.fr/doc/2008/publication-4201.pdf |
| |
